Cargando…

m(6)A regulators featured by tumor immune microenvironment landscapes and correlated with immunotherapy in non-small cell lung cancer (NSCLC)

INTRODUCTION: Recent research has confirmed the critical role that epigenetic factors play in regulating the immune response. Nonetheless, what role m(6)A methylation modification might play in the immune response of non-small cell lung cancer (NSCLC) remains vague. METHODS: Herein, the gene express...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Baowen, Qin, Hao, Zhang, Jingyao, Zhang, Min, Yang, Yunkai, Teng, Xu, Yu, Hefen, Huang, Wei, Wang, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800857/ https://www.ncbi.nlm.nih.gov/pubmed/36591468 http://dx.doi.org/10.3389/fonc.2022.1087753

Ejemplares similares

Identifying key transcription factors and immune infiltration in non-small-cell lung cancer using weighted correlation network and Cox regression analyses
por: Zhang, Jingyao, et al.
Publicado: (2023)

The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022)

Erratum: The landscape of immunotherapy resistance in NSCLC
Publicado: (2023)

Microenvironment and the progress of immunotherapy in clinical practice of NSCLC brain metastasis
por: Xie, Mengqing, et al.
Publicado: (2023)

Prognostic analysis of patients with breast cancer based on tumor mutational burden and DNA damage repair genes
por: Teng, Xu, et al.
Publicado: (2023)

Recent Advances in Immunotherapy in Metastatic NSCLC
por: Bansal, Pranshu, et al.
Publicado: (2016)

RUNX2 recruits the NuRD(MTA1)/CRL4B complex to promote breast cancer progression and bone metastasis
por: Yin, Xin, et al.
Publicado: (2022)

Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases
por: Pierret, Thomas, et al.
Publicado: (2022)

Editorial: Immunotherapy for NSCLC with oncogenic driver variants
por: Du, Yijia, et al.
Publicado: (2022)

Immunotherapy for extensive-stage small-cell lung cancer: current landscape and future perspectives
por: Zhang, Shuang, et al.
Publicado: (2023)

GEO Data Mining Identifies OLR1 as a Potential Biomarker in NSCLC Immunotherapy
por: Liu, Bin, et al.
Publicado: (2021)

The PRMT6/PARP1/CRL4B Complex Regulates the Circadian Clock and Promotes Breast Tumorigenesis
por: Yang, Tianshu, et al.
Publicado: (2023)

Current status and challenges of immunotherapy in ALK rearranged NSCLC
por: Qi, Rongbin, et al.
Publicado: (2022)

Comparison of Efficacy and Safety Between Immunotherapy and Docetaxel Monotherapy in NSCLC Patients
por: Yang, Wenchao, et al.
Publicado: (2022)

Tumour microenvironment landscape and immunotherapy response in bladder cancer decoded by stromal MOXD1 based on copper-related genes signature
por: Wang, Wenhao, et al.
Publicado: (2022)

Influence of Estrogen on the NSCLC Microenvironment: A Comprehensive Picture and Clinical Implications
por: Smida, Tanner, et al.
Publicado: (2020)

JAG1 is correlated to suppressive immune microenvironment and predicts immunotherapy resistance in lung adenocarcinoma
por: He, Jing, et al.
Publicado: (2023)

Editorial: The interconnection between the tumor microenvironment and immunotherapy in brain tumors
por: Qu, Chunrun, et al.
Publicado: (2023)

Editorial: The Biological Landscape of Immunotherapy in AML
por: Isidori, Alessandro, et al.
Publicado: (2021)

Exploring the landscape of immunotherapy approaches in sarcomas
por: Pilavaki, Pampina, et al.
Publicado: (2023)

A Ten-N(6)-Methyladenosine (m(6)A)-Modified Gene Signature Based on a Risk Score System Predicts Patient Prognosis in Rectum Adenocarcinoma
por: Huang, Wei, et al.
Publicado: (2021)

Research Progress on the Microenvironment and Immunotherapy of Advanced Non-Small Cell Lung Cancer With Liver Metastases
por: Fang, Yujia, et al.
Publicado: (2022)

Co-Occurring Alteration of NOTCH and DDR Pathways Serves as Novel Predictor to Efficacious Immunotherapy in NSCLC
por: Zhang, Zhimin, et al.
Publicado: (2021)

Comprehensive Analysis of 5-Methylcytosine (m(5)C) Regulators and the Immune Microenvironment in Pancreatic Adenocarcinoma to Aid Immunotherapy
por: Wang, Ronglin, et al.
Publicado: (2022)

Research landscape and trends of melanoma immunotherapy: A bibliometric analysis
por: Liu, Yanhao, et al.
Publicado: (2023)

Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients
por: Grenda, Anna, et al.
Publicado: (2021)

Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
por: Xiong, Anwen, et al.
Publicado: (2021)

Association of sarcopenia with survival in advanced NSCLC patients receiving concurrent immunotherapy and chemotherapy
por: Bolte, Fabian J., et al.
Publicado: (2022)

The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
por: Chu, Gerard J., et al.
Publicado: (2019)

Macrophages in Osteosarcoma Immune Microenvironment: Implications for Immunotherapy
por: Luo, Zhong-Wei, et al.
Publicado: (2020)

Review of biomarkers for response to immunotherapy in HNSCC microenvironment
por: Chen, Shaoshi, et al.
Publicado: (2023)

Editorial: Tumor microenvironment, inflammation, and resistance to immunotherapies
por: Decock, Julie, et al.
Publicado: (2023)

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
por: Peng, Lixiu, et al.
Publicado: (2023)

Acute Phase Proteins as Early Predictors for Immunotherapy Response in Advanced NSCLC: An Explorative Study
por: Schneider, Marc A., et al.
Publicado: (2022)

Machine learning identifies characteristics molecules of cancer associated fibroblasts significantly correlated with the prognosis, immunotherapy response and immune microenvironment in lung adenocarcinoma
por: Wang, Qian, et al.
Publicado: (2022)

m(6)A Regulator-Mediated Methylation Modification Model Predicts Prognosis, Tumor Microenvironment Characterizations and Response to Immunotherapies of Clear Cell Renal Cell Carcinoma
por: Xu, Wenhao, et al.
Publicado: (2021)

Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC
por: Huang, Hongxiang, et al.
Publicado: (2023)

The Tumor Microenvironment and Immunotherapy of Oropharyngeal Squamous Cell Carcinoma
por: Welters, Marij J. P., et al.
Publicado: (2020)

Immunotherapy and Targeting the Tumor Microenvironment: Current Place and New Insights in Primary Pulmonary NUT Carcinoma
por: Li, Xiang, et al.
Publicado: (2021)

SRC and MEK Co-inhibition Synergistically Enhances the Anti-tumor Effect in Both Non-small-cell Lung Cancer (NSCLC) and Erlotinib-Resistant NSCLC
por: Yuan, Man, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_t3ii6s759nssug38b42h07gha8